MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)
Status:
Unknown status
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The MyoCell™ implantation using the MyoCath™ delivery catheter system may have the potential
to add a new dimension to the management of post-infarct deterioration of cardiac function in
subjects with congestive heart failure. Based on pre-clinical studies, implantation of
autologous skeletal myoblasts may lead to replacement of non-functioning myocardial scar with
functioning muscle and improvement in myocardial performance. Preliminary data in human
subjects suggest skeletal myoblast implantation at the time of CABG may lead to the same
effects. In principal, myoblast implantation by catheter delivery may offer the same
therapeutic benefit. The present clinical study is to be conducted primarily to evaluate the
safety of MyoCell™ implantation using the MyoCath™ delivery system and secondarily to
evaluate the effect on regional myocardial function post treatment.